Protein kinase C and other diacylglycerol effectors in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Almost three decades after the discovery of protein kinase C (PKC), we still have only a partial understanding of how this family of serine/threonine kinases is involved in tumour promotion. PKC isozymes - effectors of diacylglycerol (DAG) and the main targets of phorbol-ester tumour promoters - have important roles in cell-cycle regulation, cellular survival, malignant transformation and apoptosis. How do PKC isozymes regulate these diverse cellular processes and what are their contributions to carcinogenesis? Moreover, what is the contribution of all phorbol-ester effectors, which include PKCs and small G-protein regulators? We now face the challenge of dissecting the relative contribution of each DAG signal to cancer progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC) and other effector proteins, ultimately influencing microglial processes such as migration, phagocytosis, cytokine secretion, and metabolic responses. 13 , 16 , 17”
From Alzheimer's disease–associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell–derived microglia‐like cells (2025) · cites this paper as [17]
In the citing paper
“and DAG leading to activation of protein kinase C (PKC) isozymes, the NLRP3 inflammasome [31, 34], as well as other proteins [77].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [77]
In the citing paper
“Conversely, phorbol esters, the naturally occurring activating ligands of PKC, showed tumor‐promoting functions, suggesting that PKC could be an oncogene [111, 120, 121].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [121]
Citations
Cites
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 3×
“Chimaerins (α2, β2) Rac-GAPC1SH2 PKDs (1, 2, 3) C1A C1B Protein kinasePH nPKCs (δ, ε, η, θ) Protein kinaseC2 C1A C1B ApcMin/+mouse A mouse strain harbouring a nonsense mutation at codon 850 in one allele of the Apc (adenomatous polyposis coli) gene.”
BackgroundKishimoto, A., Takai, Y., Mori, T., Kikkawa, U., & Nishizuka, Y. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85886-6 · Cited by 1,303
Protein kinase C as a possible receptor protein of tumor‐promoting phorbol esters
Kikkawa, U., Takai, Y., Tanaka, Y., Miyake, R., & Nishizuka, Y. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44245-1 · Cited by 881 · cited 2×
“Chimaerins (α2, β2) Rac-GAPC1SH2 PKDs (1, 2, 3) C1A C1B Protein kinasePH nPKCs (δ, ε, η, θ) Protein kinaseC2 C1A C1B ApcMin/+mouse A mouse strain harbouring a nonsense mutation at codon 850 in one allele of the Apc (adenomatous polyposis coli) gene.”
Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm
NEWTON, A. C. (2003) · Biochemical Journal · doi:10.1042/bj20021626 · Cited by 798
Takai, Y., Kishimoto, A., Kikkawa, U., Mori, T., & Nishizuka, Y. (1979) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(79)91197-5 · Cited by 731 · cited 1×
“Nishizuka and colleagues found that PKC could be activated by the lipid diacylglycerol (DAG) in the presence of phosphatidylserine as a cofacto”
BackgroundRasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs
Ebinu, J. O., Bottorff, D. A., Chan, E. Y. W., Stang, S. L., Dunn, R. J., & Stone, J. C. (1998) · Science · doi:10.1126/science.280.5366.1082 · Cited by 689
Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells.
Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., & Weichselbaum, R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00305.x · Cited by 670
Multiple pathways control protein kinase C phosphorylation
Parekh, D. B., Ziegler, W., & Parker, P. J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.496 · Cited by 601 · cited 1×
“The mechanisms involved in PKC activation have been extensively studie”
BackgroundTakahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 571
Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119006 · Cited by 566 · cited 1×
“Several PKC isoforms, including PKCα, β and e, are activated in response to VEGF receptor activation, and PKC has been implicated as an important mediator of VEGF-induced proliferation of endothelial cell”
Background
Research works printed but not linked: 1
- Wu, E. X. et al. PKCβ: a rational therapeutic target in diffuse large B-cell lymphoma. Blood 100, 202A–202A (2002).
Cited by
Items 301–400 of 1,000
PKCϵ Is an Essential Mediator of Prostate Cancer Bone Metastasis
Gutiérrez-Uzquiza, Á., López‐Haber, C., Jernigan, D. L., Fatatis, A., & Kazanietz, M. G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0111 · Cited by 42
“Numerous laboratories underscored important roles for PKCe in cell-cycle progression and the control of cell survival mechanisms (2, 5, 6).”
BackgroundSelf-citationGopalakrishna, R., Gundimeda, U., Schiffman, J. E., & McNeill, T. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801519200 · Cited by 42
Lanuza, M. A., Just‐Borràs, L., Hurtado, E., Cilleros‐Mañé, V., Tomàs, M., García, N., & Tomàs, J. M. (2019) · Cells · doi:10.3390/cells8121578 · Cited by 44
“IP3 leads to Ca2+ release, and, as a result, mature protein kinases C (PKCs) are cleaved to the membrane, leading to massive conformational changes in them, allowing for substrate binding, phosphorylation and downstream signaling effectors’ activations [75,76].”
BackgroundMiyanaga, A., Masuda, M., Motoi, N., Tsuta, K., Nakamura, Y., Nishijima, N., WATANABE, S.-I. J., Asamura, H., Tsuchida, A., Seike, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.027 · Cited by 42
Smith, M. D., Gong, D., Sudhahar, C. G., Reno, J. C., Stahelin, R. V., & Best, M. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8001002 · Cited by 42
Hydrogen sulfide-mediated myocardial pre- and post-conditioning
Predmore, B. L., & Lefer, D. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.56 · Cited by 43
Sarveswaran, S., & Ghosh, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.027 · Cited by 44
“Though the role of PKCε is well-known to promote survival and growth of a variety of cells including prostate cancer cells [14,20,21,38,39], mechanism of the regulation of PKCε by metabolites of 5-Lox in prostate cancer cell survival are yet to be characterized.”
Lonetti, A., Cappellini, A., Spartà, A., Chiarini, F., Buontempo, F., Evangelisti, C., Evangelisti, C., Orsini, E., McCubrey, J. A., & Martelli, A. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3295 · Cited by 43
“We observed that neither selective, nor dual or pan-inhibitors reduced phosphorylated levels of PKC isoforms [34].”
Zheng, J.-H., Koh, X., Hua, F., Li, G., Larrick, J. W., & Bian, J. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq263 · Cited by 41
A novel DLX3–PKC integrated signaling network drives keratinocyte differentiation
Palazzo, E., Kellett, M. D., Cataisson, C., Bible, P. W., Bhattacharya, S., Sun, H., McCarter, A. C., Yuspa, S. H., & Morasso, M. I. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.5 · Cited by 43
“TPA treatment induces skin inflammation and hyperproliferation through different mechanisms.(9) In order to definewhat”
BackgroundXia, J., Matsuhashi, S., Hamajima, H., Iwane, S., Takahashi, K., Eguchi, Y., Mizuta, T., Fujimoto, K., Kuroda, S., & Ozaki, I. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.010 · Cited by 41
“Altered expression of PKCs has been linked with various types of malignancies, including HCC [42–44].”
BackgroundProtein Kinase C: An Attractive Target for Cancer Therapy
Marengo, B., Ciucis, C. D., Ricciarelli, R., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2011) · Cancers · doi:10.3390/cancers3010531 · Cited by 48
“down-regulated in malignant gliomas, bladder carcinomas and endometrial tumors [73,74].”
BackgroundUllah, M. F., Bhat, S. H., Husain, E., Abuduhier, F. M., Hadi, S. M., Sarkar, F. H., & Ahmad, A. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9341-9 · Cited by 45
“…(PKC) plays essential roles in multiple cellular signal transduction pathways and in cancer cells, PKC has been known to play its vital role in tumor development and maintenance of malignant phenotype and thus has been identified as one of the prime anti-cancer targets (Griner and Kazanietz 2007).”
BackgroundNowak, G., Bakajsova, D., & Samarel, A. M. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00364.2010 · Cited by 41
McKiernan, E., O'Brien, K., Grebenchtchikov, N. I., Geurts-Moespot, A. J., Sieuwerts, A. M., Martens, J. W. M., Magdolen, V., Evoy, D., McDermott, E. W. M., Crown, J. P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604728 · Cited by 41
“Although, originally, PKCs were believed to be mostly promitotic (Griner and Kazanietz, 2007), more recent findings suggest that the effects of at least some PKCs may be isoenzyme and cell-type dependent (Jackson and Foster, 2004; Griner and Kazanietz, 2007).”
BackgroundInfluentialBryostatin-1: a promising compound for neurological disorders
Tian, Z., Lu, X.-T., Jiang, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1187411 · Cited by 43
“The dysfunction of PKC is closely associated with the pathophysiology of many diseases like cancer (Griner and Kazanietz, 2007), cardiovascular diseases (Murphy and Frishman, 2005) and neurological disorders (Etcheberrigaray et al.”
BackgroundMilestones in Skin Carcinogenesis: The Biology of Multistage Carcinogenesis
Balmain, A., & Yuspa, S. H. (2014) · Journal of Investigative Dermatology · doi:10.1038/skinbio.2014.2 · Cited by 40
“on skin cancer, these subsequent studies revealed intimate details of the PKC signal transduction pathway and its essentiality for many critical biological functions in cells and tissues (Griner and Kazanietz, 2007).”
BackgroundWu, Y., Peng, C., Huang, L., Xu, L., Ding, X., Liu, Y., Zeng, C., Sun, H., & Guo, W. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317287 · Cited by 40
Losey, E. A., Smith, M. D., Meng, M., & Best, M. D. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800414k · Cited by 44
DeCicco-Skinner, K. L., Trovato, E. L., Simmons, J. K., Lepage, P. K., & Wiest, J. S. (2010) · Oncogene · doi:10.1038/onc.2010.447 · Cited by 40
Hallmarks for senescence in carcinogenesis: novel signaling players
Caino, M. C., Meshki, J., & Kazanietz, M. G. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0316-z · Cited by 54
Self-citationProtein Kinase Cα Mediates Erlotinib Resistance in Lung Cancer Cells
Abera, M. B., & Kazanietz, M. G. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.097725 · Cited by 44
Self-citationScutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells
Gao, Z., Huang, D., Li, H., Zhang, L.-N., Lv, Y., Cui, H., & Zheng, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.034 · Cited by 40
“Because emerging evidence indicates that PKC is involved in mediating VEGF-induced angiogenesis [25,26], the inhibition of PKC would be expected to attenuate in vitro angiogenesis, which contradicts our results.”
ResultTetraspanin microdomains control localized protein kinase C signaling in B cells
Zuidscherwoude, M., Dunlock, V.-M. E., van den Bogaart, G., van Deventer, S. J., van der Schaaf, A., van Oostrum, J., Goedhart, J., Hout, J. I. ’., Hämmerling, G. J., Tanaka, S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aag2755 · Cited by 39
Xu, W., Zeng, F., Li, S., Li, G., Lai, X., Wang, Q. J., & Deng, F. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2914-9 · Cited by 41
Yanagita, R. C., Nakagawa, Y., Yamanaka, N., Kashiwagi, K., Saito, N., & Irie, K. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0706719 · Cited by 39
Burnworth, B., Pippin, J., Karna, P., Akakura, S., Krofft, R. D., Zhang, G., Hudkins, K. L., Alpers, C. E., Smith, K. D., Shankland, S. J., et al. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.199 · Cited by 39
Novel Features of DAG-Activated PKC Isozymes Reveal a Conserved 3-D Architecture
Lučić, I., Truebestein, L., & Leonard, T. A. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.11.001 · Cited by 39
Péter, M., Glatz, A., Gudmann, P., Gombos, I., Török, Z., Horváth, I., Vígh, L., & Balogh, G. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173739 · Cited by 40
Peng, Y., Chen, Z., He, Y., Li, P., Chen, Y., Chen, X., Jiang, Y., Qin, X., Li, S., Li, T., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.030 · Cited by 39
PKCα suppresses osteoblastic differentiation
Nakura, A., Higuchi, C., Yoshida, K., & Yoshikawa, H. (2010) · Bone · doi:10.1016/j.bone.2010.09.238 · Cited by 43
Leondaritis, G., Petrikkos, L., & Mangoura, D. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05975.x · Cited by 37
Dries, D. R., & Newton, A. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709943200 · Cited by 37
Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes
Nakayama, M., Sakai, K., Yamashita, A., Nakamura, T., Suzuki, Y., & Matsumoto, K. (2013) · Cytokine · doi:10.1016/j.cyto.2013.04.006 · Cited by 37
Durgan, J., Cameron, A. J. M., Saurin, A. T., Hanrahan, S. J., Totty, N., Messing, R. O., & Parker, P. J. (2008) · Biochemical Journal · doi:10.1042/bj20071348 · Cited by 37
Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia
Lin, H.-P., Chang, J.-Y., Lin, S.-R., Lee, M.-H., Huang, S., Hsu, L., & Chang, N. (2011) · Genes & Cancer · doi:10.1177/1947601911418498 · Cited by 37
Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells
Brusevold, I. J., Tveteraas, I. H., Aasrum, M., Ødegård, J., Sandnes, D., & Christoffersen, T. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-432 · Cited by 39
“PKC may be involved in cancer progression [36].”
BackgroundPrevention of carcinogenesis and inhibition of breast cancer tumor burden by dietary stearate
Li, C., Zhao, X., Toline, E. C., Siegal, G. P., Evans, L. M., Ibrahim‐Hashim, A., Desmond, R. A., & Hardy, R. W. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr092 · Cited by 39
Pan, X., Kane, L. A., Eyk, J. E. V., & Coulombe, P. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302042 · Cited by 37
Muranaka, H., Hayashi, A., Minami, K., Kitajima, S., Kohno, S., Nishimoto, Y., Nagatani, N., Suzuki, M., Kulathunga, L. A. N., Sasaki, N., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.51 · Cited by 36
Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC
Sreekumar, R., Emaduddin, M., AlSaihati, H., Moutasim, K. A., Chan, J., Spampinato, M. G., Bhome, R., Yuen, H. M., Mescoli, C., Vitale, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1885-6 · Cited by 39
Llorens, M. C., Rossi, F. A., García, I. A., Cooke, M., Abba, M. C., López‐Haber, C., Barrio‐Real, L., Vaglienti, M. V., Rossi, M., Bocco, J. L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01323 · Cited by 39
Self-citationCalcium Transduces Plasma Membrane Receptor Signals to Produce Diacylglycerol at Golgi Membranes
Kunkel, M. T., & Newton, A. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.123133 · Cited by 36
Follo, M. Y., Russo, D., Finelli, C., Mongiorgi, S., Clissa, C., Filì, C., Colombi, C., Gobbi, M., Manzoli, L., Piazzi, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.300 · Cited by 38
p120 catenin is a key effector of a Ras-PKCɛ oncogenic signaling axis
Dann, S. G., Golas, J., Miranda, M., Shi, C., Wu, J., Jin, G., Rosfjord, E. C., Upeslacis, E., & Klippel, A. (2013) · Oncogene · doi:10.1038/onc.2013.91 · Cited by 37
Mohan, R. D., Litchfield, D. W., Torchia, J., & Tini, M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1097 · Cited by 36
“The fact that both CBP/p300 and PKC signalling pathways are deregulated in oncogenesis (25,53,54) suggest that TDG may be a downstream target that may be functionally compromised and contribute to the genomic instability associated with cancer.”
FoxO-Dependent Regulation of Diacylglycerol Kinase α Gene Expression
Martínez‐Moreno, M., García-Liévana, J., Soutar, D., Torres‐Ayuso, P., Andrada, E., Zhong, X., Koretzky, G. A., Mérida, I., & Ávila‐Flores, A. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00654-12 · Cited by 40
Batarseh, A. M., Giatzakis, C., & Papadopoulos, V. (2008) · Biochemistry · doi:10.1021/bi8012643 · Cited by 40
“It is also involved in carcinogenesis (23,37-39) and participates in tumor development, metastasis, and invasion in many tissues.”
BackgroundChen, J., Giridhar, K. V., Zhang, L., Xu, S., & Wang, Q. J. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr113 · Cited by 35
Torres, M., Rosselló, C. A., Fernández‐García, P., Lladó, V., Kakhlon, O., & Escribá, P. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072322 · Cited by 38
Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases
Fazio, A., Obeng, E. O., Rusciano, I., Marvi, M. V., Zoli, M., Mongiorgi, S., Ramazzotti, G., Follo, M. Y., McCubrey, J. A., Cocco, L., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155297 · Cited by 37
“DAG and PA are involved in the regulation of several critical enzymes, including mammalian target of rapamycin (mTOR) [10], phosphatidylinositol-4-phosphate 5-kinase (PIP5K), the Ras GTPase-activating protein (GAP), rapidly accelerated fibrosarcoma-1 (Raf-1) kinase, protein kinases C (PKCs), mammalian uncoordinated 13…”
BackgroundMetabolic labeling of glycerophospholipids via clickable analogs derivatized at the lipid headgroup
Ancajas, C. F., Ricks, T. J., & Best, M. D. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.104971 · Cited by 37
Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane
Danker, K., Reutter, W. G., & Semini, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00626.x · Cited by 35
“kidney (Griner and Kazanietz, 2007).”
BackgroundChemical modifications of resveratrol for improved protein kinase C alpha activity
Das, J., Pany, S., & Majhi, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.008 · Cited by 35
Regulation of platelet plug formation by phosphoinositide metabolism
Min, S. H., & Abrams, C. S. (2013) · Blood · doi:10.1182/blood-2013-05-427716 · Cited by 38
Complanine, an inflammation-inducing substance isolated from the marine fireworm Eurythoe complanata
NAKAMURA, K. W., Tachikawa, Y., Kitamura, M., Ohno, O., Suganuma, M., & Uemura, D. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b803107j · Cited by 35
Expression of protein kinase C gamma promotes cell migration in colon cancer
Dowling, C. M., Hayes, S. L., Phelan, J. J., Cathcart, M. C., Finn, S. P., Mehigan, B. J., McCormick, P. H., Coffey, J. C., O'Sullivan, J. N., & Kiely, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18916 · Cited by 35
Identification of metabolites with anticancer properties by computational metabolomics
Arakaki, A. K., Mezencev, R., Bowen, N. J., Huang, Y., McDonald, J. F., & Skolnick, J. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-57 · Cited by 37
“For instance, diacylglycerol, a lipid that confers specific structural and dynamic properties to biological membranes and serves as a building block for more complex lipids is also an essential second messenger in mammalian cells whose dysregulation contributes to cancer progression [4].”
BackgroundDiacylglycerol Kinases and Its Role in Lipid Metabolism and Related Diseases
Liu, Y., Yang, Z., Zhou, X., Li, Z., & Hideki, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313207 · Cited by 34
Salotti, J., Dias, M. H., Koga, M. M., & Armelin, H. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072582 · Cited by 35
“PKC enzymes play important roles in several signal transduction cascades involved in cell-cycle regulation, cellular survival, malignant transformation and apoptosis [37].”
BackgroundZhang, P., Fu, C., Hu, Y., Dong, C., Song, Y., & Song, E. (2015) · Scientific Reports · doi:10.1038/srep09275 · Cited by 34
Díaz‐Valdivia, N., Bravo, D., Huerta, H., Henríquez, S., Gabler, F., Vega, M., Romero, C., Calderón, C. C., Owen, G. I., Leyton, L., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1477-5 · Cited by 34
“PKCs that promote tumor formation in two stage cancer models in mice [23].”
BackgroundModular synthesis of biologically active phosphatidic acid probes using click chemistry
Smith, M. D., Sudhahar, C. G., Gong, D., Stahelin, R. V., & Best, M. D. (2009) · Molecular BioSystems · doi:10.1039/b901420a · Cited by 34
Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Sudhahar, C. G., Haney, R. M., Xue, Y., & Stahelin, R. V. (2008) · Current Drug Targets · doi:10.2174/138945008785132420 · Cited by 38
Brain‐specific functions of the endocytic machinery
Camblor‐Perujo, S., & Kononenko, N. L. (2021) · FEBS Journal · doi:10.1111/febs.15897 · Cited by 36
Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation
Yu, Z., Xiao, H., Wang, L., Shen, X., Jing, Y., Wang, L., Sun, W.-F., Zhang, Y., Cui, Y., Shan, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1616 · Cited by 33
“PKCs have been shown to play a complex role in tumorigenesis, which is initially recognized from the tumor-promoting activity of phorbol esters in mouse skin (6).”
BackgroundTranscriptional Regulation of Oncogenic Protein Kinase Cϵ (PKCϵ) by STAT1 and Sp1 Proteins
Wang, H., Gutiérrez-Uzquiza, Á., Garg, R., Barrio‐Real, L., Abera, M. B., López‐Haber, C., Rosemblit, C., Lu, H., Abba, M. C., & Kazanietz, M. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548446 · Cited by 37
“It is widely recognized that distinct members of the diacylglycerol/phorbol ester-regulated PKCs act either as promoters or suppressors of growth and tumorigenesis (13, 14).”
BackgroundSelf-citationLi, J., Ziemba, B. P., Falke, J. J., & Voth, G. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505369r · Cited by 33
PKCδ survival signaling in cells containing an activated p21Ras protein requires PDK1
Xia, S., Chen, Z., Forman, L. W., & Faller, D. V. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.12.002 · Cited by 33
The relationship between apoptosis and aging
Lü, B., Chen, H., & Hong-Guang, H.-G. (2012) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2012.326091 · Cited by 32
“The intrinsic pathways including many hypothesis, and many factors involved in them, such as gene [4,5], DNA damage [6], some proteins [7, 8], and kinases or phosphatases [9,10], lysosomes [11], mitochondria [12], persistent stress [13], and ROS [14].”
BackgroundHui, X., Reither, G., Kaestner, L., & Lipp, P. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00040-14 · Cited by 32
“The family of PKC kinases comprises 10 isoforms: Ca(2) -sensitive or conventional and phorbol ester-responsive PKCs (cPKCs) , I, II, and ; Ca(2) -insensitive but DAG- and phorbol ester-responsive novel PKCs (nPKCs) ε, , , and ; and atypical PKC isoforms (aPKCs) and , which are regulated by different lipid derivatives…”
BackgroundLechtenberg, B. C., Gehring, M. P., Light, T. P., Horne, C. R., Matsumoto, M. W., Hristova, K. A., & Pasquale, E. B. (2021) · Nature Communications · doi:10.1038/s41467-021-27343-z · Cited by 37
Iagher, F., Belo, S. R. D. B., Souza, W. M., Nunes, J. R., Naliwaiko, K., Sassaki, G. L., Bonatto, S. J. R., de Oliveira, H. H. P., de Brito, G. A. P., de Lima, C., et al. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-146 · Cited by 32
“The anti-tumor effect of SLOil has been associated to the interaction of 1-O-alkyl2-acylglycerol, an analogue of diacylglycerol (DAG), with PKC [28].”
BackgroundInfluentialKotelevets, N., Fabbro, D., Huwiler, A., & Zangemeister‐Wittke, U. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039209 · Cited by 32
“The cellular effects associated with PKC inhibition in tumor cells include decreased proliferation, cell cycle disruption and apoptosis [30].”
BackgroundBrown, M. V., Burnett, P. E., Denning, M. F., & Reynolds, A. B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.09.025 · Cited by 33
Zhang, M., Zhang, J., Zhang, H., & Tang, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158433 · Cited by 31
RetractedIn Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma
Ren, L., Li, Z., Wang, Y., Teng, Y., Sun, H., Xing, B., Yang, X. Y., Jiang, Y., & He, F. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000421 · Cited by 31
Salama, M., Liu, M., Clarke, C. J., Espaillat, M. P., Haley, J. D., Jin, T., Wang, D., Obeid, L. M., & Hannun, Y. A. (2019) · Oncogene · doi:10.1038/s41388-019-0950-z · Cited by 31
Budas, G. R., Koyanagi, T., Churchill, E. N., & Mochly‐Rosen, D. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351021 · Cited by 31
PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells
Lamontagne, C., & Grandbois, M. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.07.013 · Cited by 31
Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene
Burns, T. A., Subathra, M., Signorelli, P., Choi, Y. L., Yang, X., Wang, Y., Villani, M., Bhalla, K. N., Zhou, D., & Luberto, C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m033985 · Cited by 35
Irie, K., Yanagita, R. C., & Nakagawa, Y. (2010) · Medicinal Research Reviews · doi:10.1002/med.20220 · Cited by 34
“Another advantage in using PKC activators as therapeutic leads is that they target the C1 domains characteristic of PKCs, though recent investigations revealed the presence of several targets other than PKCs with similar C1 domains: protein kinase D (PKD), diacylglycerol kinases (DGKs), RasGRPs, chimaerins, Unc13s, an…”
BackgroundKassahn, D., Nachbur, U., Conus, S., Micheau, O., Schneider, P., Simon, H.-U., & Brunner, T. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.133 · Cited by 31
Adams, S., & Munz, B. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.10.006 · Cited by 31
Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs
Bessone, M. I. D., Berardi, D. E., Campodónico, P. B., Todaro, L. B., Lothstein, L., Joffé, E. B. D. K., & Urtreger, A. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0956-2 · Cited by 30
“There are only few studies, including our own, pointing out a pro-survival or anti-apoptotic role for PKCd in different cell types, even conferring a more malignant phenotype and cytotoxic drug resistance [6, 10, 34, 35].”
BackgroundYin, H., Wang, X., Guo, Y., Zhou, Y., & Ai, S. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.11.014 · Cited by 30
Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma
Kikuchi, K., Soundararajan, A., Zarzabal, L. A., Weems, C. R., Nelon, L. D., Hampton, S. T., Michalek, J. E., Rubin, B. P., Fields, A. P., & Keller, C. (2012) · Oncogene · doi:10.1038/onc.2012.46 · Cited by 30
“PKC isozymes play crucial roles in diverse cellular signaling processes including cellular proliferation, differentiation, apoptosis and angiogenesis (7).”
BackgroundAfrasiabi, E., Ahlgren, J., Bergelin, N., & Törnquist, K. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.018 · Cited by 35
“PKC-mediated ignal transduction pathways convert extracellular stimulation into variety of cellular functions (Griner and Kazanietz, 2007).”
Tikhmyanova, N., Schultz, D., Lee, T. M., Salvino, J. M., & Lieberman, P. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4006326 · Cited by 30
“ribosomal kinases, such as p90RSK and S6 (29).”
BackgroundPKC ϵ Is Required for KRAS-Driven Lung Tumorigenesis
Garg, R., Cooke, M., Wang, S., Benavides, F., Abba, M. C., Cicchini, M., Feldser, D. M., & Kazanietz, M. G. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1300 · Cited by 30
Self-citationWu-Zhang, A. X., Murphy, A. N., Bachman, M., & Newton, A. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.412635 · Cited by 29
“In addition, we found that overexpression of PKC , which has been shown to oppose both the apoptotic (2) and metabolic (30) effects of PKC , actively decreases mitochondrial respiration relative to vector control (Fig.”
BackgroundCui, Z., Piao, J., Kondo, T., Ogawa, R., Tsuneyama, K., Zhao, Q., Feril, L. B., & Inadera, H. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.03.005 · Cited by 29
Schmidt, V. A. (2012) · International Journal of Hepatology · doi:10.1155/2012/958673 · Cited by 29
“All PKCs are major targets of tumor promoting phorbol esters and diacylglycerol (DAG) in response to the activation of growth factor receptors [70].”
BackgroundLipid levels in sperm, eggs, and during fertilization in Xenopus laevis
Petcoff, D. W., Holland, W. L., & Stith, B. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800159-jlr200 · Cited by 29
PKC Delta and Epsilon in Drug Targeting and Therapeutics
Yonezawa, T., Kurata, R., Kimura, M., & Inoko, H. (2009) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221509788654205 · Cited by 29
“PKC activation has been shown to be involved in pathological states such as cancer [5], pain [6], diabetes [7, 8] cardiac attack [9, 10], stroke [11, 12], Alzheimer’s disease [13], heart failure [14], angiogenesis [15] and regulation of the”
BackgroundUeda, Y., Makino, A., Murase‐Tamada, K., Sakaï, S., Inaba, T., Hullin‐Matsuda, F., & Kobayashi, T. (2013) · The FASEB Journal · doi:10.1096/fj.12-226548 · Cited by 28
The PKC universe keeps expanding: From cancer initiation to metastasis
Rahimova, N., Cooke, M., Zhang, S., Baker, M. J., & Kazanietz, M. G. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100755 · Cited by 29
Self-citationGarg, R., Caino, M. C., & Kazanietz, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067319 · Cited by 28
“The PKC family comprises at least 10 related serinethreonine kinases with extensive functional diversity, and it has been classified into classical (cPKCs a, bI, bII and c), novel (nPKCs d, e, g and h), and atypical (aPKCsf and l/i) based on the structural and biochemical properties of the different isozymes [1,2].”
Self-citationSun, X., Lu, B., Hu, B., Xiao, W., Li, W., & Huang, Z. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.18 · Cited by 28
Ozawa, T., Osaka, I., Ihozaki, T., Hamada, S., Kuroda, Y., Murakami, T., Miyazato, A., Kawasaki, H., & Arakawa, R. (2015) · Journal of Mass Spectrometry · doi:10.1002/jms.3700 · Cited by 32
Metadata
- Authors
- Griner, E. M., & Kazanietz, M. G.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Kazanietz, Marcelo G.
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 281-294
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1987496015
- Cited by
- 978
- References
- 190
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 16 · 2023: 28 · 2022: 32 · 2021: 35 · 2020: 47 · 2019: 35 · 2018: 46 · 2017: 56 · 2016: 55 · 2015: 44 · 2014: 80 · 2013: 66 · 2012: 71
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- protein kinase C, diacylglycerol, phorbol ester, tumor promotion, carcinogenesis, tumor progression, cell cycle regulation, apoptosis, malignant transformation, cell survival, small GTPases, signal transduction
- MeSH terms
- Cell Cycle, Diglycerides, Enzyme Activation, Humans, Isoenzymes, Neoplasms, Neovascularization, Pathologic, Peptide Hydrolases, Phorbol Esters, Protein Kinase C, Apoptosis, GTP Phosphohydrolases, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.